JY
TCRR

Jeff Yass’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Jeff Yass’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-65,000
Closed -$65K – 13964
2022
Q4 		$65K Sell
65,000
-23,400
-26% -$31.5K ﹤0.01% 11249
2022
Q3 		$159K Buy
88,400
+23,700
+37% +$68.7K ﹤0.01% 11162
2022
Q2 		$188K Buy
+64,700
New +$160K ﹤0.01% 10730
2021
Q4 		– Sell
-42,200
Closed -$359K – 14225
2021
Q3 		$359K Buy
42,200
+31,000
+277% +$438K ﹤0.01% 10187
2021
Q2 		$184K Sell
11,200
-3,000
-21% -$60.6K ﹤0.01% 11683
2021
Q1 		$314K Sell
14,200
-41,900
-75% -$1.14M ﹤0.01% 10509
2020
Q4 		$1.74M Buy
56,100
+22,000
+65% +$556K ﹤0.01% 5398
2020
Q3 		$693K Buy
+34,100
New +$599K ﹤0.01% 6980

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Jeff Yass's TCRR Position: Q1 2022 in Review

Jeff Yass sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q1 2022, closing a stake of 77,501 shares — an estimated $361K sold.

Jeff Yass first reported a position in TCRR in Q1 2020 and held it in 8 quarters. The position peaked at $1.28M in Q4 2020. 94 funds tracked by Wall St. Rank hold TCRR as of Q1 2022.

  • Jeff Yass reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Jeff Yass sold 77,501 TCR2 Therapeutics Inc. Common Stock shares in Q1 2022, an estimated $361K.
  • Jeff Yass first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2020 and held it in 8 quarters.
  • Jeff Yass's TCR2 Therapeutics Inc. Common Stock position peaked at $1.28M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q1 2022.

Based on Susquehanna International Group's 13F filing for Q1 2022, filed 16 May 2022.